The Online International  Journal of Onco Scientific Networks & Oncology is a peer-reviewed open acess journal that publishes original research articles as well as review articles in all areas of Oncology. this practical journal also includes information on new products, new therapies and patient management, as well as reviews of the latest research. Cancer is a complex problem. The international effort to understand and control it involves clinicians trained in many branches of medicine and scientists from most biological disciplines, chemistry, pharmaceutical and physical sciences The International Online Journal of Cancer & Therapeutics exists to serve the needs of this diverse community, providing a forum for prompt communication of original and innovative research findings that have relevance to understanding the etiology of cancer and to improving the treatment and survival of patients.

The journal publishes important original studies, reviews, and perspectives within the major topic areas of biology of premalignancy, risk factors and risk assessment, early detection research, immunoprevention, and chemopreventive and other interventions, including the basic science behind them. This journal comprises preclinical, clinical and translational research, with special attention given to molecular discoveries and an emphasis on building a translational bridge between the basic and clinical sciences. Main focuses of interest include: systemic anticancer therapy (with specific interest on molecular targeted agents and new immune therapies), randomized trials (including negatives ones), top-level guidelines, and new fields currently emerging as key components of personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Radiotherapy, surgery and pediatrics manuscripts can be considered if they display a clear interaction with one of the fields above or are paradigm-shifting.

Oncology is the diagnosis and treatment of cancers,including breast,prostate,colon,lung and ovarian cancers as well as brain tumors,leukemia,lymphoma and many other types of cancer.. A doctor who works in the field of oncology is called an oncologist. The primary regions of oncology are radiation, which is worried with radiation treatment, or radiotherapy; surgical, which is contained specialists who spend significant time in tumor evacuation; therapeutic, which manages disease drugs, including chemotherapy; and interventional, which includes interventional radiologists who have some expertise in insignificantly obtrusive picture guided tumor treatment.




Veria Khosrawipour

General Surgeon

2003 - High-school graduation, Schiller-Schule Bochum, Germany
2003-2009 - Medical School, Ruhr-University Bochum 
2007-2009 - Dissertation: Prognostic role of high-sensitive C-reactive protein                    regarding general and cardiovascular mortality in outpatients
11.2009 - German Medical Board Exam and Medical License
2009-2010 - Passing of USMLE Step 1 and 2 (United States Medical Licensing   Examination)
09/2011-04/2012 - Residenc,Department of Neurosurgery, University Hospital Göttingen, Germany, Director: Prof. Dr. V. Rohde
08/2012-09/2013 - Residency, Department of Orthopedic and Trauma Surgery, St. Josef Hospital Bochum, Director: Prof. Dr. C. von Schulze-Pellengahr
10/2013-3/2014 - Clinical Rotation, Department of Trauma Surgery, Bergmannsheil Bochum, University Hospital of the Ruhr-University Bochum,   Director: Prof. Dr. T. Schildhauer
04/2014-12/2016 - Residency,Department of General and Special Visceral Surgery, Surgical Oncology, Center for Peritoneal Carcinomatosis, Marienhospital Herne, Germany, University Hospital of the Ruhr-University Bochum, Director: Prof. Dr. J. Zieren
Since 01/2017 - Fellowship, Department for Special Orthopedic Surgery and Trauma Surgery, Orthoclinic Dortmund, Director: Dr. M. Danaei

  • German Society for Surgery (DGS)
  • German Society for Orthopedic and Trauma surgery (DGOU)
  • German Cancer Society (DKG)

            Active member of visceral oncology group

  • Chamber of Physicians, Nordrhine-Westphalia, Germany
  • American Society for Peritoneal Surface Malignancies (ASPSD)

[1]Díaz-Carballo D, Klein J, Acikelli AH, Wilk C, Saka S, Jastrow H, Wennemuth G, Dammann P, Giger-Pabst U, Khosrawipour V, Rassow J, Nienen M, Strumberg D. Cytotoxic stress induces transfer of mitochondria-associated human endogenous retroviral RNA and proteins between cancer cells.Oncotarget. 2017 Oct 7;8(56):95945-95964.
[2] Khosrawipour T, Khosrawipour V, Giger-Pabst U. Pressurized Intra Peritoneal Aerosol Chemotherapy in patients suffering from peritoneal carcinomatosis of pancreatic adenocarcinoma.PLoS One. 2017 Oct 19;12(10)
[3] Khosrawipour T, Wu D, Bellendorf A, Mohanaraja N, Karabay E, Diaz-Carballo D, Khosrawipour V.Feasibility of Single Tumorspot Treatment in Peritoneal Carcinomatosis via Close Range Doxorubicin Impaction in Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC). J Clin Exp Oncol Jan 2017 6; (3).
[4]Bellendorf A*, Khosrawipour V*, Khosrawipour T, Siebigteroth S, Cohnen J, Diaz-Carballo D, Bockisch A, Zieren J, Giger-Pabst U. Scintigraphic peritoneography reveals a non-uniform 99mTc-Pertechnetat aerosol distribution pattern for Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) in a swine model.
Surg Endosc. 2017 Jun 22. [Epub ahead of print]
[5] Khosrawipour V, Khosrawipour T, Hedayat-Pour Y ,Diaz-Carballo D, Bellendorf A, Böse-Ribeiro H, Mücke R, Mohanarajra N, Adamietz IA, Fakhrian K. Effect of Whole abdominal radiation on  Penetration Depth of Doxorubicin in Normal Tissue After Pressurized Intraperitoneal AerosolChemotherapy (PIPAC) in a Post mortem Swine model. Anticancer Res. 2017 [accepted for publication]
[6]Göhler D, Khosrawipour V, Khosrawipour T, Diaz-Carballo D, Falkenstein TA, Zieren J, Stintz M, Giger-Pabst U. Technical description of the microinjection pump (MIP®) and granulometric characterization of the aerosol applied for pressurized intraperitoneal aerosol chemotherapy (PIPAC).Surg Endosc. 2017 Apr;31(4):1778-1784.
[7] Khosrawipour V, Diaz-Carballo D, Ali-Haydar A, Khosrawipour T, Falkenstein TA, Wu D, Zieren J, Giger-Pabst U. Cytotoxic effect of different treatment parameters in pressurized intraperitoneal aerosol chemotherapy (PIPAC) on the in vitro proliferation of human colonic cancer cells.World J Surg Oncol. 2017 Feb 10;15(1):43.
[8] Khosrawipour V, Khosrawipour T, Kern AJ, Osma A, Kabakci B, Diaz-Carballo D, Förster E, Zieren J, Fakhrian K. Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model.J Cancer Res Clin Oncol. 2016 Nov;142(11):2275-80.
[9] Khosrawipour V, Khosrawipour T, Falkenstein TA, Diaz-Carballo D, Förster E, Osma A, Adamietz IA, Zieren J, Fakhrian K. Evaluating the Effect of Micropump© Position, Internal Pressure and Doxorubicin Dosage on Efficacy of Pressurized Intra-peritoneal Aerosol Chemotherapy (PIPAC) in an Ex Vivo Model. Anticancer Res. 2016 Sep;36(9):4595-600.
[10] Khosrawipour V, Bellendorf A, Khosrawipour C, Hedayat-Pour Y, Diaz-Carballo D, Förster E, Mücke R, Kabakci B, Adamietz IA, Fakhrian K. Irradiation Does Not Increase the Penetration Depth of Doxorubicin in Normal Tissue After Pressurized Intra-peritoneal Aerosol Chemotherapy (PIPAC) in an Ex Vivo Model. In Vivo. 2016 09-10;30(5):593-7.
[11] Khosrawipour V, Giger-Pabst U, Khosrawipour T, Pour YH, Diaz-Carballo D, Förster E, Böse-Ribeiro H, Adamietz IA, Zieren J, Fakhrian K. Effect of Irradiation on Tissue Penetration Depth of Doxorubicin after Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) in a Novel Ex-Vivo ModelJ Cancer. 2016 May 7;7(8):910-4.
[12] Khosrawipour V, Khosrawipour T, Diaz-Carballo D, Förster E, Zieren J, Giger-Pabst U.Exploring the Spatial Drug Distribution Pattern of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC).Ann Surg Oncol. 2016 Apr;23(4):1220-4.
[13] Welsch J, Kup PG, Nieder C, Khosrawipour V, Bühler H, Adamietz IA, Fakhrian K.Survival and Symptom Relief after Palliative Radiotherapy for Esophageal Cancer. J Cancer. 2016 Jan 1;7(2):125-30.
[14] Díaz-Carballo D, Acikelli AH, Klein J, Jastrow H, Dammann P, Wyganowski T, Guemues C, Gustmann S, Bardenheuer W, Malak S, Tefett NS, Khosrawipour V, Giger-Pabst U, Tannapfel A, Strumberg D.Therapeutic potential of antiviral drugs targeting chemorefractory colorectal adenocarcinoma cells overexpressing endogenous retroviral elements. J Exp Clin Cancer Res. 2015 Aug 12;34:81.